Logo Logo
Help
Contact
Switch Language to German

Lange, T.; Krahl, R.; Grünhagen, U. von; Al-Ali, H. K.; Schwarzer, A.; Jentsch-Ullrich, K.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M. and Niederwieser, D. (2017): Imatinib (IM) in combination with Hydroxyurea in patients with CML1st CP does not increase molecular response at 18 months compared to IM alone. Final results of the OSHO CML2004 study. NCT 02480608. In: Oncology Research and Treatment, Vol. 40: pp. 121-122

Full text not available from 'Open Access LMU'.

Actions (login required)

View Item View Item